|
Budding Upcoming Sales of Nuvilex, Inc. (NVLX)
Cancer Treatments Render Investment in Technology Worth
It
As Nuvilex, Inc. (OTCQB:
NVLX) persistently primes for its Phase III pancreatic cancer
trials, the nearly $30-million it has invested in its
exclusive and one-of-a-kind living cell encapsulation or
“Cell-in-a-Box” technology could be assets well invested given
the return in annual sales that cancer medications beget in the
marketplace.
The first type the company is choosing to
challenge is advanced pancreatic cancer – a market that Eli
Lilly’s medication Gemzar has cornered and yields about
$1.4-billion yearly.
Nuvilex has about $25-million invested in two independent Phase II clinical
trials in patients with advanced, inoperable pancreatic
cancer using the combination of the broadly-used anticancer medication,
ifosfamide, and encapsulated cells capable of changing the ifosfamide, into
its “cancer-killing” form as well as for preclinical studies
researching the potential use of the cell encapsulation technology in the
advancement of treatments for other cancers and other diseases. Also, the
company has earmarked almost another
$2-million into advancing the development of the
“Cell-in-a-Box” technology.
This
is a pretty large price tag for such a small biotech, but with the outcomes
the company has seen in its two clinical trials, the future looks very
hopeful. In those trials, the outcomes are outperforming the current gold
standard, the aforementioned Eli Lilly’s medicine
Gemzar.
Cancer medications are big business, and
those medications are even bigger business when they are successful, and
when they prolong lives, and so far, Nuvilex’s cell encapsulation
technology has shown it does work and it does prolong lives.
A glance at the significant outcomes in those two trials
demonstrate that with twenty-seven patients included, a substantial
response was seen in that the use of the living cell
encapsulation-ifosfamide grouping helped patients to a better outcome than
that previously reported with standard single-medication (Gemzar) therapy.
Outcomes from these trials included; average survival time and one-year
survival rate were almost doubled as equated to
historical data for Gemzar. The gravity of ifosfamide's side effects was
lessened because only one-third of its normal dose was used. No harm to
tissues adjacent to the capsules was seen. Cells inside the capsules were
guarded from harm by the patients’ immune systems. Cells inside the
capsules were alive and functioning – even after more than two
years.
And, this is only the treatment for advanced
pancreatic cancer which is as harsh a disease as you can find – what
about using this technology as a remedy for other types of cancer?
Nuvilex’s “Cell-in-a-Box” technology could make its mark
enhancing on the industry norm in one kind of cancer after the other, and
when you start to consider the billions being generated each year in those
medicines, that undoubtedly makes the technology well worth the investment
to date.
Unsubscribe
| Disclaimer
10200 Forest Green Blvd, Suite 112, Louisville, Kent. 40223
USA
![]()
|